Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands

British Journal of Pharmacology

Volumn 125, Issue 1, 1998, Pages 175-185

  Boronat, M Assumpció ^a   Olmos, Gabriel ^a   García Sevilla, Jesús A ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

2 adrenoceptor antagonists; Cytoskeleton; I2 imidazoline receptors; Idazoxan; Morphine; N methyl D aspartate receptors; Neurofilament proteins; Neuroprotection; Pentazocine; Tolerance

Indexed keywords

2 (2 BENZOFURANYL)IMIDAZOLE; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; DELEQUAMINE; DIZOCILPINE; IDAZOXAN; IMIDAZOLINE I2 RECEPTOR; MORPHINE; MOXONIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROFILAMENT PROTEIN; PENTAZOCINE; ROMIFIDINE; TRACIZOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG TOLERANCE; MALE; MORPHINE TOLERANCE; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

ADRENERGIC ALPHA-ANTAGONISTS; ANALGESICS, OPIOID; ANIMALS; BENZOFURANS; BRAIN; DRUG TOLERANCE; IDAZOXAN; IMIDAZOLES; LIGANDS; MALE; MORPHINE; NEUROFILAMENT PROTEINS; PAIN MEASUREMENT; PENTAZOCINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0031656862     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702031     Document Type: Article

References (77)

1. 2 receptors, on glial fibrillary acidic protein concentration. Eur. J. Pharmacol., 280, 205-210.
2. 3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Naunyn-Schmiedeberg's Arch. Pharmacol., 356, 39-47.
3. BEITNER-JOHNSON, D., GUITART, X. & NESTLER, E.J. (1992). Neurofilament proteins and the mesolimbic dopamine system: common regulation by chronic morphine and chronic cocaine in the rat ventral tegmental area. J. Neurosci., 12, 2165-2176.
4. BEITNER-JOHNSON, D., GUITART, X. & NESTLER, E.J. (1993). Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area. J. Neurochem., 61, 1766-1773.
5. BEITNER-JOHNSON, D. & NESTLER, E.J.(1993a). Chronic morphine impairs mesolimbic transport in the rat mesolimbic dopamine system. NeuroReport, 5, 57-60.
6. BEITNER-JOHNSON, D. & NESTLER, E.J. (1993b). Chronic morphine decreases insulin-like growth factor-I levels in the ventral tegmental area of the rat brain. Ann. New York Acad. Sci., 692, 246-248.
7. BERSHOW, M.T., RUSSELL, D.S., TERWILLIGER, R.Z., BEITNER-JOHNSON, D., SELF, D.W., LINDSAY, R.M. & NESTLER, E.J. (1995). Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience, 68, 969-979.
8. 2-imidazoline ligands attenuates the development of tolerance to morphine-induced antinociception in rats. Br. J. Pharmacol., in press.
9. BOUSQUET, P. (1995). Imidazoline receptors: from basic concepts to recent developments. J. Cardiovasc. Pharmacol., 26, S1-S6.
10. BRADFORD, M.M. (1976). A rapid sensitive method for the quantification of protein using the principle of protein dye binding. Anal. Biochem., 72, 248-252.
11. 2-adrenoceptor or μ-opioid receptor mechanisms. Eur. J. Pharmacol., 331, 133-138.
12. 3H]-clonidine to identify imidazoline receptors in the rabbit brainstem. Br. J. Pharmacol., 110, 1537-1543.
13. 2-adrenoceptor antagonist. Br. J. Pharmacol., 108, 516-525.
14. BUISSON, A., PLOTKINE, M. & BOULU, R.G. (1992). The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia. Br. J. Pharmacol., 106, 766-767.
15. ω-Nitro-L-arginine methyl ester of motoneuron cell death after neonatal axotomy. Neuroscience, 71, 313-325.
16. 2-mediated analgesia and other non-cardiovascular therapeutic uses. Life Sci., 2, 63-74.
17. CONTRERAS, E., TAMAYO, L. & AMIGO, M. (1988). Calcium channel antagonists increase morphine-induced analgesia and antagonize morphine tolerance. Eur. J. Pharmacol., 148, 463-466.
18. D'AMOUR, F.E. & SMITH, D.L. (1941). A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther., 72, 74-79.
19. DAWSON, G., DAWSON, S.A. & GOSWAMI, R. (1997). Chronic exposure to κ-opioids enhances the susceptibility of immortalized neurons (F-II κ7) to apoptosis-inducing drugs by a mechanism that may involve ceramide. J. Neurochem., 68, 2363-2370.
20. 2 receptors. Eur. J. Pharmacol., 333, 9-15.
21. DINGLEDINE, R. & MCBAIN, C.J. (1994). Excitatory amino acid transmitters. In Basic Neurochemistry.eds. Siegel, G.J., Agranoff, B.W., Albers, R.W. & Molinoff, P.B. pp. 367-399. New York: Raven Press.
22. 2-adrenoceptors. Br. J. Pharmacol., 78, 489-505.
23. ELLIOT, K., KEST, B., MAN, A., KAO, B. & INTURRISI, C.E. (1995). N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology, 13, 347-356.
24. 2 subtypes. Fundam. Clin. Pharmacol., 6 (suppl 1), 55s, P18.
25. 1-imidazoline sites. J. Pharmacol. Exp. Ther., 264, 172-182.
26. 2 sites in the mammalian central nervous system. Pharmacol. Ther., 68, 175-208.
27. 3H]-RX821002, a 2-methoxy derivative of idazoxan. Br. J. Pharmacol., 100, 862-866.
28. GARCÍA-SEVILLA, J.A., VENTAYOL, P., BUSQUETS, X., LA HARPE, R., WALZER, C. & GUIMÓN, J. (1997). Marked decrease of immunolabelled 68 kDa neurofilament (NF-L) proteins in brains of opiate addicts. NeuroReport, 8, 1561-1565.
29. GILAD, G.M., SALAME, K., RABEY, J.M. & GILAD, V.H. (1996). Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci., 58, PL 41-46.
30. GOLD, B.G., GRIFFIN, J. & PRICE, D.L. (1985). Slow axonal transport in acrylamide neuropathy: different abnormalities produced by single-dose and continuous administration. J. Neurosci., 5, 1755-1768.
31. GOSWAMI, R., DAWSON, S.A. & DAWSON, G. (1998). Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis in both embryonic and immortalized (F-11κ7) neurons. J. Neurochem., 70, 1376-1382.
32. + + uptake. J. Pharmacol. Exp. Ther., 209, 132-136.
33. 2-adrenergic receptor antagonist, decreases neuronal damage in the rat brain. J. Cereb. Blood Flow Metab., 9, 171-174.
34. HAUSER, K.F. & STIENE-MARTIN, A. (1991). Characterization of opioid-dependent glial development in dissociated and organotypic cultures of mouse central nervous system: critical periods and target specificity. Dev. Brain Res., 62, 245-255.
35. HERMAN, B., VOCCI, F. & BRIDGE, P. (1995). The effects of NMDA receptor antagonists and nitric oxide inhibitors on opioid tolerance and withdrawal. Neuropsychopharmacology, 13, 269-293.
36. HOFFMAN, P.N., GRIFFIN, J.W. & PRICE, D.L. (1994). Control of axonal caliber by neurofilament transport. J. Cell. Biol., 99, 705-714.
37. 2 imidazoline ligand, RS 45041, potentiates hyperalgesia in acute arthritis. NeuroReport, 7, 1497-1501.
38. 2-sites). Br. J. Pharmacol., 114, 411P.
39. KELLSTEIN, D.E. & MAYER, D.J. (1991). Spinal co-administration of cholecystokinin antagonists with morphine prevents the development of opioid tolerance. Pain, 47, 221-229.
40. KOLESNIKOV, Y., JAIN, S. & PASTERNAK, G.W. (1996). Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol., 296, 17-22.
41. 2-site ligand, 2-(-2-benzofuranyl)-2-imidazoline, on in vivo noradrenaline release in rat brain. Br. J. Pharmacol., 114, 413P.
42. LEE, M.K. & CLEVELAND, D.W. (1996). Neuronal intermediate filaments. Annu. Rev. Neurosci., 19, 187-217.
43. LI, G., REGUNATHAN, S., BARROW, C.J., ESHRAGHI, J., COOPER, R. & REIS, D.J. (1994). Agmatine an endogenous clonidine-displacing substance in the brain. Science, 263, 966-969.
44. 2-adrenoceptors in the human heart: discrimination by clonidine and moxonidine. Naunyn-Schmiedeberg's Arch. Pharmacol., 354, 689-692.
45. LIUZZI, F.J. & TEDESCHI, B. (1992). Axo-glial interactions at the dorsal root transitional zone regulate neurofilament protein synthesis in axotomized sensory neurons. J. Neurosci., 12, 4783-4792.
46. MAIESE, K., PEK, L., BERGER, S.B. & REIS, D.J. (1992). Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J. Cereb. Blood Flow Metab., 12, 53-63.
47. MCPHERSON, G.A. (1985). Analysis of radioligand binding experiments: a collection of computer programs for IBM PC. J. Pharmacol. Meth., 14, 213-228.
48. MESHUL, C.K., SEIL, F.J. & HERNDON, R.M. (1987). Astrocytes play a role in regulation of synaptic density. Brain Res., 402, 139-145.
49. MICHEL, M.C. & INSEL, P.A. (1989). Are there multiple imidazoline binding sites? Trends Pharmacol Sci., 10, 342-344.
50. 3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J. Pharmacol. Exp. Ther., 264, 1187-1197.
51. MOLDERINGS, G.J. (1997). Imidazoline receptors: basic knowledge, recent advances and future prospects for therapy and diagnosis. Drugs Fut. 22, 757-772.
52. MONROE, P.J., SMITH, D.L., KIRK, H.R. & SMITH, D.J. (1995). Spinal nonadrenergic imidazoline receptors do not mediate the anti-nociceptive action of intrathecal clonidine in the rat. J. Pharmacol. Exp. Ther., 273, 1057-1062.
53. MUNSON, P.J. & RODBARD, D. (1980). LIGAND: a versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem., 107, 220-239.
54. NESTLER, E.J., BERHOW, M.T. &, BRODKIN, E.S. (1996). Molecular mechanism of drug addiction: adaptations in signal transduction pathways. Mol. Psychiat., 1, 190-199.
55. ODERFELD-NOWAK, B., BACIA, A., GRADKOWSKA, M., FUSCO, M., VANTINI, G., LEON, A. & ALOE, L. (1992). In vivo activated brain astrocytes may produce and secrete nerve growth factor-like molecules. Neurochem. Int., 21, 455-461.
56. OLMOS, G., ALEMANY, R., ESCRIBÁ, P.V. & GARCÍA-SEVILLA, J.A. (1994). The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. Br. J. Pharmacol., 111, 997-1002.
57. OLMOS, G., RIBERA, J. & GARCÍA-SEVILLA, J.A. (1996). Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain. Eur. J. Pharmacol., 310, 273-276.
58. 2-imidazoline receptors in rat liver. Br. J. Pharmacol., 121, 901-912.
59. PILETZ, J.E., CHIKKALA, D.N. & ERNSBERGER, P. (1995). Comparison of the properties of agmaline and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J. Pharmacol. Exp. Ther., 272, 581-587.
60. REGUNATHAN, S., FEINSTEIN, D.L., RAASCH, W. & REIS, D.J. (1995). Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. NeuroReport, 6, 1897-1900.
61. REGUNATHAN, S., FEINSTEIN, D.L. & REIS, D.J. (1993). Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. J. Neurosci. Res., 34, 681-688.
62. REGUNATHAN, S. & REIS, D.J. (1996). Imidazoline receptors and their endogenous ligands. Annu. Rev. Pharmacol. Toxicol., 36, 511-544.
63. RUGGIERO, D.A., REGUNATHAN, S., WANG, H., MILNER, T.A. & REIS, D.J. (1998). Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res., 780, 270-293.
64. SAKAGUCHI, T., OKADA, M., KITAMURA, T. & KAWASAKI, K. (1993). Reduced diameter and conduction velocity of myelinated fibers in the sciatic nerve of a neurofilament-deficient mutant quail. Neurosci. Lett., 153, 65-68.
65. 2-imidazoline receptors in the postmortem brains of heroin addicts. NeuroReport, 7, 509-512.
66. 2 blockade by idazoxan increases insulin and lowers plasma glucose during positron emission tomography. Psychopharmacol. Bull., 33, 253-259.
67. 2 adrenoceptor blockade by idazoxan in healthy male and female volunteers. Psychoneuroendocrinology, 22, 177-188.
68. SELF, D.W. & NESTLER, E.J. (1995). Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci., 18, 463-495.
69. SKLAIR-TAVRON, L., SHI, W.X., LANE, S.B., HARRIS, H.W., BUNNEY, B.S. & NESTLER, E.J. (1996). Chronic morphine induces visible changes in the morphology of mesolimbic dopamine neurons. Proc. Natl. Acad. Sci. USA, 93, 11202-11207.
70. STIENE-MARTIN, A. & HAUSER, K.F. (1993). Morphine suppresses DNA synthesis in cultured murine astrocytes from cortex, hippocampus and striatum. Neurosci. Lett., 157, 1-3.
71. TESSON, F. & PARINI, A. (1991). Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex. Eur. J. Pharmacol., 208, 81-83.
72. TESSON, F., PRIP-BUUS, C., LEMOINE, A. PEGORIER, J.-P. & PARINI, A. (1991). Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. J. Biol. Chem., 266, 155-160.
73. TISEO, P.J., CHENG, J., PASTERNAK, G.W. & INTURRISI, C.E. (1994). Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J. Pharmacol. Exp. Ther., 268, 195-201.
74. TRUJILLO, K.A. (1995). Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology, 13, 301-307.
75. TRUJILLO, K.A. & AKIL, H. (1991). Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 251, 85-87.
76. VENTAYOL, P., BUSQUETS, X. & GARCÍA-SEVILLA, J.A. (1997). An antisense oligodeoxynucleotide against protein kinase C-α abolishes morphine-induced analgesia in rats. Meth. Find. Exp. Clin. Pharmacol., 19 (suppl A), 154 (PB-3).
77. WELCH, S.P. & OLSON, K.G. (1991). Opiate tolerance-induced modulation of free intracellular calcium in synaptosomes. Life Sci., 48, 1853-1861.